Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 481 to 482 of 482 entries
Sorted by: Best Match Show Resources per page
Grape Pomace: A Potential Ingredient for the Human Diet.

Foods (Basel, Switzerland)

Pereira P, Palma C, Ferreira-Pêgo C, Amaral O, Amaral A, Rijo P, Gregório J, Palma L, Nicolai M.
PMID: 33260373
Foods. 2020 Nov 29;9(12). doi: 10.3390/foods9121772.

The industrial production of wine generates annually tons of waste that can and must be properly reused to reduce its polluting load ad increase the availability of passive ingredients to be used in human nutrition. Grape pomace, a by-product...

Cite
Pereira P, Palma C, Ferreira-Pêgo C, et al. Grape Pomace: A Potential Ingredient for the Human Diet. Foods. 2020;9(12)doi: 10.3390/foods9121772.
Pereira, P., Palma, C., Ferreira-Pêgo, C., Amaral, O., Amaral, A., Rijo, P., Gregório, J., Palma, L., & Nicolai, M. (2020). Grape Pomace: A Potential Ingredient for the Human Diet. Foods (Basel, Switzerland), 9(12), . https://doi.org/10.3390/foods9121772
Pereira, Paula, et al. "Grape Pomace: A Potential Ingredient for the Human Diet." Foods (Basel, Switzerland) vol. 9,12 (2020). doi: https://doi.org/10.3390/foods9121772
Pereira P, Palma C, Ferreira-Pêgo C, Amaral O, Amaral A, Rijo P, Gregório J, Palma L, Nicolai M. Grape Pomace: A Potential Ingredient for the Human Diet. Foods. 2020 Nov 29;9(12). doi: 10.3390/foods9121772. PMID: 33260373; PMCID: PMC7760011.
Copy Download .nbib Format: NLM
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.

Cancers

Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P.
PMID: 34885249
Cancers (Basel). 2021 Dec 06;13(23). doi: 10.3390/cancers13236141.

(1) Background: Immune checkpoint inhibitors have improved the prognosis of patients with advanced melanoma. Published data suggested that the objective response rates appear to be superior in patients who developed immune-related adverse events (irAEs). (2) The primary aim of...

Cite
Serna-Higuita LM, Amaral T, Forschner A, et al. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236141.
Serna-Higuita, L. M., Amaral, T., Forschner, A., Leiter, U., Flatz, L., Seeber, O., Thomas, I., Garbe, C., Eigentler, T. K., & Martus, P. (2021). Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers, 13(23), . https://doi.org/10.3390/cancers13236141
Serna-Higuita, Lina María, et al. "Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236141
Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel). 2021 Dec 06;13(23). doi: 10.3390/cancers13236141. PMID: 34885249; PMCID: PMC8657404.
Copy Download .nbib Format: NLM
Showing 481 to 482 of 482 entries